Giant Ventures

Giant Ventures

Giant Ventures was founded in 2018 by Cameron McLain and Tommy Stadlen. McLain previously co-founded The Rise Fund's advisory arm, while Stadlen was an early employee at Quillette and an advisor to various impact ventures. The firm's name reflects its thesis: backing entrepreneurs who can build giant companies that solve giant problems. The firm invests at seed and Series A stages across ClimateTech, Digital Health, and Enterprise Software, with a purposeful emphasis on mission-driven business models. Confirmed portfolio companies include Healx (AI-driven rare disease drug discovery), Pachama (carbon offset verification via satellite data), and Dendron (data infrastructure for AI). Giant Ventures typically leads or co-leads rounds, often alongside other impact-focused venture funds, and maintains a network of LP entrepreneurs for follow-on capital. Giant Ventures has not publicly disclosed AUM or total professionals. The team operates from offices in London, Princeton, and the San Francisco Bay Area. In 2023, the firm closed a second fund at an undisclosed size, continuing its thematic focus on climate and health. The partners have also built a community of operators and scientists they call the "Giant Fellowship," designed to source deals and support portfolio companies. A structural differentiator is Giant Ventures' systematic co-investment model with its limited partners, many of whom are successful founders themselves. The firm also pools a portion of carried interest into a charitable fund, creating alignment with its mission-driven thesis. This hybrid structure — combining traditional VC returns with impact measurement — places Giant Ventures in the same orbit as firms like Obvious Ventures and The Engine, but with a distinct Atlantic-spanning footprint.